RA0090

antibody from Oursmab

Targeting: CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0090

Provider

Oursmab

Product name

Vadastuximab (Biosimilar Reference Antibody) (CD33)

Antibody type

Monoclonal

Description

Vadastuximab talirine (SGN-CD33A) is an antibody-drug conjugate (ADC) targeting CD33, a transmembrane protein expressed on myeloid cells and overexpressed in acute myeloid leukemia (AML). It consists of a humanized anti-CD33 antibody linked to a cytotoxic DNA-crosslinking agent (pyrrolobenzodiazepine dimer). Upon binding to CD33, the ADC is internalized, releasing the payload to induce apoptosis in AML cells. It was investigated for the treatment of AML, but clinical development was discontinued due to safety concerns, including increased mortality in trials.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Vadastuximab (Biosimilar Reference Antibody) (CD33)-RA0090-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Vadastuximab (Biosimilar Reference Antibody) (CD33)-RA0090 in a linear range of 15.63¨C125 ng/mL.